2/11
06:12 pm
gh
James Van Der Beek died at 48 after being diagnosed with colorectal cancer. Here's what to know about common symptoms, which can be subtle. [Business Insider]
Low
Report
James Van Der Beek died at 48 after being diagnosed with colorectal cancer. Here's what to know about common symptoms, which can be subtle. [Business Insider]
2/3
04:05 pm
gh
Guardant Health to Participate in Upcoming Investor Conferences
Medium
Report
Guardant Health to Participate in Upcoming Investor Conferences
2/2
08:13 am
gh
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions [Yahoo! Finance]
Low
Report
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions [Yahoo! Finance]
2/2
08:05 am
gh
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
Low
Report
Largest Published Study of Molecular Residual Disease (MRD) in Stage III Colon Cancer Shows Guardant Reveal Blood Test More Precisely Identifies Risk of Recurrence After Surgery to Support Timely Treatment Decisions
1/31
12:42 am
gh
Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration [Yahoo! Finance]
Low
Report
Assessing Guardant Health (GH) Valuation After FDA Guardant360 CDx Approval And New Merck Collaboration [Yahoo! Finance]
1/30
10:58 am
gh
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at UBS Group AG.
1/29
04:05 pm
gh
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
Medium
Report
Guardant Health to Report Fourth Quarter and Full Year 2025 Financial Results on February 19, 2026
1/29
01:41 pm
gh
Alger Small Cap Focus Fund Q4 2025 Portfolio Update [Seeking Alpha]
Low
Report
Alger Small Cap Focus Fund Q4 2025 Portfolio Update [Seeking Alpha]
1/26
10:02 am
gh
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Guardant Health (NASDAQ:GH) had its "buy" rating reaffirmed by analysts at Guggenheim.
1/26
09:36 am
gh
Guardant Health: Look For Explosive Revenue Growth Ahead [Seeking Alpha]
Low
Report
Guardant Health: Look For Explosive Revenue Growth Ahead [Seeking Alpha]
1/23
07:09 pm
gh
Omics Lab Services: Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Agilent Technologies, Q2 Solutions, Flomics Biotech, QIAGEN, Thermo Fisher Scientific and More [Yahoo! Finance]
Low
Report
Omics Lab Services: Global Market Review 2021-2025 and Forecast 2026-2031 Featuring Profiles of Agilent Technologies, Q2 Solutions, Flomics Biotech, QIAGEN, Thermo Fisher Scientific and More [Yahoo! Finance]
1/22
09:21 am
gh
Guardant nabs approval for Guardant360 companion diagnostic for Braftovi [Seeking Alpha]
Low
Report
Guardant nabs approval for Guardant360 companion diagnostic for Braftovi [Seeking Alpha]
1/22
08:17 am
gh
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]
Low
Report
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer [Yahoo! Finance]
1/22
08:05 am
gh
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Low
Report
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
1/20
05:27 am
gh
Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build [Yahoo! Finance]
Low
Report
Analysts Turn More Bullish on Guardant Health, Inc. (GH) as 2026 Growth Catalysts Build [Yahoo! Finance]
1/19
08:05 am
gh
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
Low
Report
Guardant Health Announces Multi-Year Strategic Collaboration Agreement with Merck to Develop Companion Diagnostics and Commercialize New Cancer Therapies Using Guardant Infinity Smart Platform
1/18
05:23 am
gh
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth [Seeking Alpha]
Low
Report
Guardant Health: Shield Colorectal Cancer Screening To Sustain Growth [Seeking Alpha]
1/11
07:40 pm
gh
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results [Yahoo! Finance]
Low
Report
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results [Yahoo! Finance]
1/11
05:00 pm
gh
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
Low
Report
Guardant Health Announces Preliminary Fourth Quarter and Full Year 2025 Results
1/11
02:42 am
gh
How Recent Analyst Targets Are Shaping The Evolving Story For Guardant Health (GH) [Yahoo! Finance]
Low
Report
How Recent Analyst Targets Are Shaping The Evolving Story For Guardant Health (GH) [Yahoo! Finance]
1/11
01:26 am
gh
Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH) [Yahoo! Finance]
Low
Report
Guggenheim Analyst is Bullish on Guardant Health, Inc. (GH) [Yahoo! Finance]
1/10
11:37 pm
gh
Guardant Health (GH) Is Up 8.3% After TRICARE Adds No-Copay Shield Coverage For Service Members [Yahoo! Finance]
Low
Report
Guardant Health (GH) Is Up 8.3% After TRICARE Adds No-Copay Shield Coverage For Service Members [Yahoo! Finance]
1/10
07:35 pm
gh
Is Guardant Health (GH) Share Surge Justified By Recent Valuation Signals? [Yahoo! Finance]
Low
Report
Is Guardant Health (GH) Share Surge Justified By Recent Valuation Signals? [Yahoo! Finance]
1/9
09:13 am
gh
Guardant Health (NASDAQ:GH) was given a new $135.00 price target on by analysts at Mizuho.
Low
Report
Guardant Health (NASDAQ:GH) was given a new $135.00 price target on by analysts at Mizuho.
1/9
09:02 am
gh
Guardant Health (NASDAQ:GH) was given a new $120.00 price target on by analysts at Stifel Nicolaus.
Low
Report
Guardant Health (NASDAQ:GH) was given a new $120.00 price target on by analysts at Stifel Nicolaus.